[Long-term levodopa syndrome. Report of a clinical case].
Since it is was first described by James Parkinson in 1817 much has been learnt about Parkinson's disease. The complete picture is not clear, however, and a new impulse has been given to the study of the physiopathology of the basal ganglia by the therapeutic employment of L-Dopa with a peripheral inhibitor of the decarboxylase. This treatment is the best available particularly for akinetic-hypertonic forms. In certain cases, however, patients developed a dyskinetic long-term L-Dopa syndrome, depending on the amount of L-Dopa given and individual sensitivity. The syndrome occurs in Parkinsonism only and can be prevented by thalamolysis. It would appear to be a specific expression of the effect of L-Dopa on the striatonigral system rather than of generic hypersensitivity due to denervation. A personal case is presented.
D001479:Basal Ganglia / Q000187:drug effects; D004409:Dyskinesia, Drug-Induced; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D010302:Parkinson Disease, Secondary / Q000188:drug therapy*; D013997:Time Factors
D007980:Levodopa
Long-term levodopa syndrome. Alcune considerazioni e presentazione di un caso clinico.